Shares of CureVac were up about 25% on Monday after its CEO Franz-Werner Haas said in an interview with German financial news site Boerse Online over the weekend that he hopes the vaccine will be approved by regulators early next year. Haas added that even an “accelerated approval was possible”. …
Read More »